Research

The following research projects were developed using data from the granulosa cell tumor database.

External link (opens in new tab) Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models
External link (opens in new tab) Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors
External link (opens in new tab) Survival outcomes comparing minimally invasive versus open cytoreductive surgery in recurrent adult-type granulosa cell tumors
External link (opens in new tab) Survival outcomes in patients with recurrent mixed sex cord-stromal tumors of the ovary
External link (opens in new tab) Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors
External link (opens in new tab) TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors

Sood Laboratory

Dr. Anil K. Sood is a Professor in the Department of Gynecologic Oncology and Reproductive Medicine at UT MD Anderson, where he has held multiple leadership roles, including co-director of the Center for RNA Interference and Non-Coding RNA, Director of the Blanton-Davis Ovarian Cancer Research Program, and co-lead of the Ovarian Cancer Moon Shot Program. His research is broadly focused on understanding cancer biology and translating laboratory discoveries into innovative therapeutics. Within this portfolio, Dr. Sood has a growing interest in granulosa cell tumors, a rare and understudied subset of ovarian malignancies. His work in this area is aimed at defining the unique molecular and microenvironmental features that drive tumor initiation, progression, and recurrence. By leveraging advanced platforms such as multi-omics profiling and spatial analyses, his team seeks to uncover novel, targetable pathways and develop rational therapeutic strategies tailored to this disease. Ultimately, his goal is to bridge critical gaps in biological understanding and accelerate the development of effective, mechanism-based therapies for patients with granulosa cell tumors.